For years, international expansion in the medical device sector followed a predictable yet inefficient path.
Each new market meant restarting regulatory processes, duplicating technical documentation, and navigating different requirements, often with little added value in terms of quality or safety.
The outcome was clear: delays, increased costs, and, most importantly, slower patient access to innovation.
That model, however, is being steadily replaced by a more intelligent and inevitable approach: regulatory reliance.
From Redundancy to Regulatory Efficiency
At its core, reliance’s built on a simple but powerful idea: regulatory authorities can leverage assessments already conducted by trusted agencies as part of their own decision-making processes.
This doesn’t mean giving up regulatory sovereignty.
On the contrary, it allows authorities to focus on what truly matters. Local context. Specific risks. Healthcare system needs. All while avoiding duplication of well-established technical evaluations.
In practice? This represents a structural shift in how medical devices are regulated globally.
The Strategic Impact on the Industry
For companies, this transformation goes far beyond regulatory affairs. It reshapes how market access strategies are designed.
Three key impacts stand out:
1. Reduced redundancy and greater operational efficiency
Harmonizing evidence across markets significantly decreases the need for multiple independent submissions.
2. Increased regulatory predictability
Greater alignment between authorities provides clearer visibility on how approvals in reference markets influence other jurisdictions.
3. Faster time-to-market
Less duplication translates into shorter timelines between development and commercialization, which is a critical factor in an increasingly competitive industry.
However, one point deserves attention: companies that fail to adapt to this logic risk losing relevance.
Trust: The Foundation of the Model
Despite its advantages, reliance still faces a central challenge: building trust among regulatory authorities.
Issues such as data confidentiality, transparency, and technical alignment remain sensitive topics.
That’s why the most successful models adopt a progressive approach, starting with lower-risk products, bilateral agreements, and pilot initiatives.
The evolution’s gradual, but consistent.
From Regulatory to Strategic: A Shift in Mindset
One of the biggest mistakes organizations can make right now? Treating reliance as purely a regulatory topic.
In reality, it requires a broader strategic mindset.
Companies must begin thinking globally from the earliest stages of development, structuring evidence consistently, aligning requirements across markets, and anticipating regulatory pathways.
This shift impacts:
- How clinical studies are designed
- How technical documentation’s structured
- How markets are prioritized
- And ultimately, how companies position themselves competitively
What Comes Next
The advancement of reliance isn’t theoretical. It’s already happening.
Driven by increasing technological complexity, particularly with software and AI-enabled devices, this model’s expected to expand and consolidate as a global standard.
In this context, regulatory collaboration’s no longer optional.
It’s operationally necessary.
Conclusion: Competitive Advantage Starts Before Submission
If there’s one clear takeaway, it’s this: competitive advantage in the medical device sector’s being built earlier than ever.
It doesn’t start at submission.
It starts with strategy.
Companies that successfully integrate regulatory intelligence, global vision, and technical consistency will be better positioned to navigate this new environment.
Others?
They’ll continue operating within a model that’s gradually becoming obsolete.
Find out more about BPO in RA! 
*Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 
